Natera's Signatera Test Wins Japan PMDA Approval for Bladder Cancer

Key Facts

1Natera received approval from Japan's PMDA for its Signatera test as a companion diagnostic for muscle-invasive bladder cancer.

2The company plans to commercially launch the test in Japan in 2027.

In a move reflecting the global expansion of molecular diagnostic technologies, Natera has received approval from Japan's PMDA for its Signatera test. According to reports, the test is approved as a companion diagnostic for muscle-invasive bladder cancer to assist in clinical treatment decisions. The company intends to officially launch the test commercially in Japan in 2027.

This regulatory milestone strengthens Natera's international footprint in the oncology sector, paving the way for long-term revenue growth in a major healthcare market. Per market data and analyst facts, the approval validates the company's expansion strategy outside the US, though the 2027 launch timeline suggests that immediate financial impacts may be deferred.

Natera (NTRA) shares stood at $390.90 at the close of September 22, 2026, having traded between a day low of $365.20 and a high of $391.93. With no immediate sector-specific catalysts in the upcoming economic calendar, investors will likely focus on technical support and resistance levels following this regulatory update.